Neurocrine Q3 2026 revenue up 41% to $1.1 billion and Ingrezza guidance raised
FROM THE WIRE · FINANCE.YAHOO.COM
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong results with raised guidance for a mid-cap biopharmaceutical company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter revenue grew 41% year over year to $1.1 billion.
- 02The 2026 Ingrezza net sales guidance was raised to $2.9 to $2.925 billion.
- 03Net product sales exceeded $1 billion for the first time.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets